Featured Research

from universities, journals, and other organizations

First Human Trial Tests Stem-cell-based Treatment For Heart Attacks

Date:
March 28, 2007
Source:
American College of Cardiology
Summary:
Previous research on the efficacy of stem cell therapy for heart repair has shown possible benefit from mesenchymal stem cells (MSCs) -- cells found in bone marrow that create connective tissue, bone and cartilage. A recent study reveals the results of the first human trial using MSCs for the treatment of myocardial infarction (MI, or heart attack).

Despite the enduring controversy surrounding the use of embryonic stem cells for disease research, scientists continue to evaluate the therapeutic potential of other types of stem cells. Previous research on the efficacy of stem cell therapy for heart repair has shown possible benefit from mesenchymal stem cells (MSCs) -- cells found in bone marrow that create connective tissue, bone and cartilage. A study presented at the American College of Cardiology's Innovation in Intervention: i2 Summit reveals the results of the first human trial using MSCs for the treatment of myocardial infarction (MI, or heart attack).

Related Articles


As a cell-based therapy, MSCs have a number of unique advantages: they can be taken from genetically distinct donors, are easy to prepare, and have a tendency to collect within injured areas. In animal models, MSCs not only home to regions of MI, but reduce infarct size and improve ejection fraction -- the portion of blood that is pumped out of the heart as a result of a heartbeat, and a primary indicator of the heart's health.

Researchers from ten medical centers across the United States, led by Joshua Hare, M.D., of the University of Miami, Miller School of Medicine, conducted a Phase 1 trial to assess the safety and efficacy of infusing MSCs intravenously to 53 patients within ten days of a heart attack. In the trial, patients were randomized to one of three doses: 0.5, 1.6 or 5 million MSCs/kg, and each dose was compared with placebo. The occurrence of treatment-related serious adverse events was evaluated over a six-month period, and efficacy was assessed using echocardiography.

Over the six month follow-up period, the stem cell-treated patients had lower rates of side effects such as cardiac arrhythmias, and had significant improvements in heart, lung and global function. Echocardiography showed improved heart function, particularly in those with large amounts of cardiac damage.

"This trial makes an important contribution in the field of stem cell-based treatments for heart disease by providing safety and efficacy data for a unique and promising type of stem cell to treat cardiac damage," said Joshua Hare, M.D., of the University of Miami and lead author of the study. "It's important to note that this study represents a first step, and, as in other disease categories, we must perform additional, larger trials to determine the real world application of mesenchymal stem cell therapy to fight heart disease."

Reference: Dr. Joshua Hare. "A Double-Blind, Randomized, Placebo Controlled Clinical Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Patients With Acute Myocardial Infarction" American College of Cardiology's Innovation in Intervention: i2 Summit in New Orleans, La.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "First Human Trial Tests Stem-cell-based Treatment For Heart Attacks." ScienceDaily. ScienceDaily, 28 March 2007. <www.sciencedaily.com/releases/2007/03/070326121246.htm>.
American College of Cardiology. (2007, March 28). First Human Trial Tests Stem-cell-based Treatment For Heart Attacks. ScienceDaily. Retrieved October 31, 2014 from www.sciencedaily.com/releases/2007/03/070326121246.htm
American College of Cardiology. "First Human Trial Tests Stem-cell-based Treatment For Heart Attacks." ScienceDaily. www.sciencedaily.com/releases/2007/03/070326121246.htm (accessed October 31, 2014).

Share This



More Health & Medicine News

Friday, October 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Melafind: Spotting Melanoma Without a Biopsy

Melafind: Spotting Melanoma Without a Biopsy

Ivanhoe (Oct. 31, 2014) The MelaFind device is a pain-free way to check suspicious moles for melanoma, without the need for a biopsy. Video provided by Ivanhoe
Powered by NewsLook.com
Battling Multiple Myeloma

Battling Multiple Myeloma

Ivanhoe (Oct. 31, 2014) The answer isn’t always found in new drugs – repurposing an ‘old’ drug that could mean better multiple myeloma treatment, and hope. Video provided by Ivanhoe
Powered by NewsLook.com
Chronic Inflammation and Prostate Cancer

Chronic Inflammation and Prostate Cancer

Ivanhoe (Oct. 31, 2014) New information that is linking chronic inflammation in the prostate and prostate cancer, which may help doctors and patients prevent cancer in the future. Video provided by Ivanhoe
Powered by NewsLook.com
Sickle Cell: Stopping Kids’ Silent Strokes

Sickle Cell: Stopping Kids’ Silent Strokes

Ivanhoe (Oct. 31, 2014) Blood transfusions are proving crucial to young sickle cell patients by helping prevent strokes, even when there is no outward sign of brain injury. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins